| 0.0701 -0.002 (-2.64%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.09 | 1-year : | 0.12 |
| Resists | First : | 0.08 | Second : | 0.1 |
| Pivot price | 0.07  |
|||
| Supports | First : | 0.05 | Second : | 0.04 |
| MAs | MA(5) : | 0.07 |
MA(20) : | 0.06 |
| MA(100) : | 0.3 |
MA(250) : | 3.02 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 54.4 |
D(3) : | 52.9 |
| RSI | RSI(14): 37.4 |
|||
| 52-week | High : | 21.39 | Low : | 0.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ONCO ] has closed above bottom band by 45.2%. Bollinger Bands are 92.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 108 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.08 - 0.08 | 0.08 - 0.08 |
| Low: | 0.06 - 0.06 | 0.06 - 0.06 |
| Close: | 0.07 - 0.07 | 0.07 - 0.07 |
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Wed, 30 Apr 2025
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - Bluefield Daily Telegraph
Wed, 30 Apr 2025
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewswire
Wed, 30 Apr 2025
Critical Alert: Onconetix Hit With Second Nasdaq Delisting Notice as Deadline Looms - Stock Titan
Fri, 18 Apr 2025
Onconetix faces Nasdaq delisting over low share price - Investing.com
Tue, 08 Apr 2025
Major Pipeline Expansion: Onconetix to Acquire FDA-Approved Eye Drug in Ocuvex Deal - Stock Titan
Tue, 08 Apr 2025
Onconetix Inks Letter Of Intent For Potential Business Combination With Ocuvex - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 1,630 (K) |
| Shares Short P.Month | 623 (K) |
| EPS | -87.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.07 |
| Profit Margin | 0 % |
| Operating Margin | -650.4 % |
| Return on Assets (ttm) | -19.2 % |
| Return on Equity (ttm) | -201.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.02 |
| Sales Per Share | 0.04 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.01 |
| Price to Sales | 1.66 |
| Price to Cash Flow | -0.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|